Search

Your search keyword '"SGLT2–inhibitors"' showing total 2 results
Start Over Descriptor "SGLT2–inhibitors" Language french
2 results on '"SGLT2–inhibitors"'

1. Innovations 2022 en néphrologie

Author

Fernandes, Guillaume, Akachar, Yassin, Labriola, Laura, Jadoul, Michel, Demoulin, Nathalie, Morelle, Johann, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, and UCL - SSS/IREC/SLUC - Pôle St.-Luc

Subjects
Inhibiteurs du système rénine-angiotensine, Dapagliflozine, Néphropathie à IgA, Inhibiteurs SGLT2, Finerenone, IgA nephropathy, Empagliflozine, Chronic kidney disease, SGLT2-inhibitors, Renin-angiotensin-system blockers, Inhibiteurs du système rénine, Albuminuria, Maladie rénale chronique, Albuminurie, Nefecon
Abstract

Nous discutons les résultats négatifs d’un essai randomisé contrôlé de l’arrêt des inhibiteurs de l’enzyme de conversion ou des sartans dans la maladie rénale chronique au stade G4 ou G5. Nous discutons ensuite les modalités d’initiation du traitement par dapagliflozine et finerenone dans la maladie rénale chronique. Enfin, nous revoyons les progrès récents dans le traitement de la néphropathie à IgA.

Published
2023

2. [Evolution of the non-insulin therapeutic strategy in type 2 diabetes].

Author

Vatier C and Bourcigaux N

Subjects
Adult, Humans, Young Adult, Middle Aged, Aged, Hypoglycemic Agents therapeutic use, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 complications, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Metformin therapeutic use, Cardiovascular Diseases drug therapy
Abstract

While the prevalence of diabetes continues to rise worldwide, with 537 million adults aged 20-79-years-old having diabetes in 2021, the development of new therapeutic classes improving not only glycemic control but also kidney function and cardiovascular prevention has revolutionized patient care. Today, the treatment of diabetes is no longer just the treatment of blood sugar level. In this context, the individualized therapeutic strategy has been completely reviewed, with in particular sulfamides indicated much later in the therapeutic strategy, while SGLT2 inhibitors are indicated very early in patients with kidney disease and/or with ischemic heart disease or chronic heart failure, and GLP-1 analogues in obese patients and/or in primary or secondary cardiovascular prevention. As for lifestyle rules and metformin, they remain the cornerstone of treatment. Knowledge of antidiabetic effects in terms of efficacy and hypoglycemic risk, of cardiovascular, nephroprotective and weight effects is essential to optimize the management of diabetic patients today., (Copyright © 2023 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results